DaVita Inc(DVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 5:05 PM ET (Korea 9/11 06:05)
Full metrics table
| Index | S&P 500 | P/E | 15.29 | EPS (ttm) | 11.86 | Insider Own | 2.07% | Shs Outstand | 63.8M | Perf Week | 1.08% |
| Market Cap | 11.57B | Forward P/E | 10.63 | EPS next Y | 14.9% | Insider Trans | -54.43% | Shs Float | 62.5M | Perf Month | 1.68% |
| Enterprise Value | 26.05B | PEG | 0.47 | EPS next Q | 3.58 | Inst Own | 93.61% | Short Float | 6.41% | Perf Quarter | -8.67% |
| Income | 0.82B | P/S | 0.83 | EPS this Y | 37.71% | Inst Trans | -3.66% | Short Ratio | 4.83 | Perf Half Y | 17.13% |
| Sales | 14.01B | P/B | - | EPS next 5Y | 22.62% | ROA | 4.67% | Short Interest | 4.00M | Perf YTD | 59.61% |
| Book/sh | -13.03 | P/C | 14.99 | EPS past 3/5Y | 18.56% 8.29% | ROE | 635.3% | 52W High | -26.73% ($247.49) | Perf Year | 37.1% |
| Cash/sh | 12.1 | P/FCF | 7.19 | Sales past 3/5Y | 5.53% 3.39% | ROIC | 6.81% | 52W Low | 79.53% ($101.00) | Perf 3Y | 89.77% |
| Dividend Est. | - | EV/EBITDA | 9.3 | EPS Y/Y TTM | 16.3% | Gross Margin | 27.29% | Volatility(W/M) | 2.8% 2.65% | Perf 5Y | 47.36% |
| Dividend TTM | - | EV/Sales | 1.86 | Sales Y/Y TTM | 6.45% | Oper. Margin | 14.93% | ATR (14) | 5.57 | Perf 10Y | 184.89% |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | EPS Q/Q | 55.84% | Profit Margin | 5.87% | RSI (14) | 42.39 | Recom | 2.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.47 | Sales Q/Q | 5.17% | SMA20 | 1.42% ($178.79) | Beta | 0.79 | Target Price | $227.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/4 | SMA50 | -11.97% ($205.99) | Rel Volume | 0.66 | Prev Close | $183.01 |
| Employees | 78000 | LT Debt/Eq | - | EPS/Sales Surpr. | 3.55% 1.65% | SMA200 | 9.85% ($165.07) | Avg Volume(3M) | 0.83M | Price | $181.33 |
| IPO | 1995/10/31 | Option/Short | Yes/Yes | Trades | 9097 | Volume | 544,207 | Change | -0.92% |
Company
DVA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A leading U.S. provider of dialysis services, specializing in kidney care. The company operates a nationwide network of hemodialysis centers for patients with chronic kidney failure and offers related treatments and medical services, making it one of America's premier dialysis service companies.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
DVA makes money exceptionally well
14.93% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.7% this year.
Tap to view numbers
The stock looks undervalued
Trading at 15.3 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +89.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 93.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
OMAH 0.04%
AZTD 0.03%
FXH 0.02%
XHYH 0.02%
SAGP 0.02%It ranks #4 in the industry
Based on market cap of $12B.
DVA $12B PER 15.3
HCA $91B PER 14.1
THC $21B PER 10.2
EHC $12B PER 19.7
FAQ
What kind of company is DVA?
DVA belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of DVA?
The market cap of DVA is approximately $11.6B, ranking 858 within its sector.
What is the P/E ratio of DVA?
DVA has a P/E ratio of approximately 15.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DVA?
DVA has recorded a 52-week high of $247.49 and a low of $101.00.
